Institut for Biomedicin

Tove Christensen

Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

Standard

Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. / Gold, J; Marta, MC; Meier, UC; Christensen, Tove; Miller, D; Altmann, D; Holden, D; Bianchi, L; Adiutori, R; MacManus, D; Yousry, T; Schmierer, K; Turner, B; Giovannoni, G.

I: Multiple Sclerosis Journal, Bind 22 SIII, 2016, s. 188-189.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

Harvard

Gold, J, Marta, MC, Meier, UC, Christensen, T, Miller, D, Altmann, D, Holden, D, Bianchi, L, Adiutori, R, MacManus, D, Yousry, T, Schmierer, K, Turner, B & Giovannoni, G 2016, 'Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results', Multiple Sclerosis Journal, bind 22 SIII, s. 188-189.

APA

Gold, J., Marta, MC., Meier, UC., Christensen, T., Miller, D., Altmann, D., Holden, D., Bianchi, L., Adiutori, R., MacManus, D., Yousry, T., Schmierer, K., Turner, B., & Giovannoni, G. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. Multiple Sclerosis Journal, 22 SIII, 188-189.

CBE

Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L, Adiutori R, MacManus D, Yousry T, Schmierer K, Turner B, Giovannoni G. 2016. Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. Multiple Sclerosis Journal. 22 SIII:188-189.

MLA

Vancouver

Author

Gold, J ; Marta, MC ; Meier, UC ; Christensen, Tove ; Miller, D ; Altmann, D ; Holden, D ; Bianchi, L ; Adiutori, R ; MacManus, D ; Yousry, T ; Schmierer, K ; Turner, B ; Giovannoni, G. / Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. I: Multiple Sclerosis Journal. 2016 ; Bind 22 SIII. s. 188-189.

Bibtex

@article{f374f117fb3d4ad5947c0c84a855dadd,
title = "Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results",
author = "J Gold and MC Marta and UC Meier and Tove Christensen and D Miller and D Altmann and D Holden and L Bianchi and R Adiutori and D MacManus and T Yousry and K Schmierer and B Turner and G Giovannoni",
year = "2016",
language = "English",
volume = "22 SIII",
pages = "188--189",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
note = "null ; Conference date: 14-09-2016 Through 17-09-2016",

}

RIS

TY - ABST

T1 - Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results

AU - Gold, J

AU - Marta, MC

AU - Meier, UC

AU - Christensen, Tove

AU - Miller, D

AU - Altmann, D

AU - Holden, D

AU - Bianchi, L

AU - Adiutori, R

AU - MacManus, D

AU - Yousry, T

AU - Schmierer, K

AU - Turner, B

AU - Giovannoni, G

PY - 2016

Y1 - 2016

M3 - Conference abstract in journal

VL - 22 SIII

SP - 188

EP - 189

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

Y2 - 14 September 2016 through 17 September 2016

ER -